These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9250567)

  • 1. Torsades de pointes with administration of high-dose intravenous d-sotalol to a patient with congestive heart failure.
    Gottlieb SS; Cines M; Marshall J
    Pharmacotherapy; 1997; 17(4):830-1. PubMed ID: 9250567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotalol-induced torsades de pointes in patients with renal failure.
    Dancey D; Wulffhart Z; McEwan P
    Can J Cardiol; 1997 Jan; 13(1):55-8. PubMed ID: 9039065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
    Yalta K; Turgut O; Yilmaz A; Yilmaz MB; Kendirlioglu O; Karadas F
    Int J Cardiol; 2007 Apr; 116(3):e95-7. PubMed ID: 17126428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.
    D'Aloia A; Faggiano P; Brentana L; Boldini A; Pedrinazzi C; Procopio R; Dei Cas L
    Int J Cardiol; 2005 Dec; 105(3):337-9. PubMed ID: 15985302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes.
    Letsas KP; Efremidis M; Sideris A
    Int J Cardiol; 2008 Mar; 124(3):366-7; author reply 368-9. PubMed ID: 17400314
    [No Abstract]   [Full Text] [Related]  

  • 7. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Torsade de Pointes tachycardia during sotalol treatment of a patient with normal potassium levels].
    Appel JM; Sigurd B
    Ugeskr Laeger; 1996 Jul; 158(28):4093-4. PubMed ID: 8701528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sotalol and torsades de pointes ventricular tachycardia].
    Petersen HH; Sandøe E
    Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torsades de Pointes: a rare complication of an extra-adrenal pheochromocytoma.
    Methe H; Hinterseer M; Wilbert-Lampen U; Beckmann BM; Steinbeck G; Kääb S
    Hypertens Res; 2007 Dec; 30(12):1263-6. PubMed ID: 18344633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes.
    Michiels V; Miljoen H; Vrints C
    Acta Cardiol; 2009 Dec; 64(6):839-42. PubMed ID: 20128168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sotalol-induced torsade de pointes tachycardia in a 15-month-old infant].
    Sasse M; Paul T; Bergmann P; Kallfelz HC
    Z Kardiol; 1995 Oct; 84(10):863-6. PubMed ID: 7502575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amiodarone versus sotalol for atrial fibrillation.
    Zimetbaum PJ; Josephson ME
    N Engl J Med; 2005 Aug; 353(6):627-30; author reply 627-30. PubMed ID: 16094764
    [No Abstract]   [Full Text] [Related]  

  • 19. Seventy-four defibrillations for sotalol-induced torsades de pointes.
    Sürücü H; Tatli E; Değirmenci A; Gökmen G
    Indian Heart J; 2004; 56(4):340-2. PubMed ID: 15586745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of the Risk of Torsades de Pointes in patients treated with intravenous racemic sotalol.
    Marill KA; Runge T
    Acad Emerg Med; 2001 Feb; 8(2):117-24. PubMed ID: 11157286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.